尼莫地平减轻多发性硬化模型中的功能障碍与脱髓鞘
该研究探讨多发性硬化(MS)模型中的组织缺氧原因及尼莫地平的治疗作用。在实验性自身免疫性脑脊髓炎(EAE)模型中,脊髓炎症部位灌注不足导致组织缺氧,尼莫地平可恢复脊髓氧合并快速改善功能,同时在EAE和早期MS病灶模型中减少脱髓鞘。
要点
- EAE中脊髓炎症部位灌注不足导致组织缺氧,是功能障碍和脱髓鞘的部分原因。
- 尼莫地平可恢复脊髓氧合、快速改善功能并减少脱髓鞘。
- 尼莫地平可能被重新用于MS治疗以提供显著临床获益。
核心结论
- EAE中的功能障碍和脱髓鞘至少部分归因于局部脊髓灌注不足所致的组织缺氧。
- 改善血流的治疗不仅保护神经功能,还能减少脱髓鞘。
- 尼莫地平可能被重新用于MS以提供显著临床获益。
研究设计与样本
- 在EAE模型中测量基础心血管生理、脊髓氧合、线粒体功能和组织灌注。
- 在EAE和早期MS病灶模型中评估尼莫地平对功能、脊髓氧合和脱髓鞘的影响。
主要发现
- EAE中的组织缺氧与炎症脊髓的严重灌注不足相关。
- 尼莫地平治疗可恢复脊髓氧合并快速改善功能。
- 尼莫地平治疗减少EAE和早期MS病灶模型中的脱髓鞘。
临床怎么用
- 尼莫地平可能作为改善MS急性功能障碍和减少脱髓鞘的候选治疗,但需进一步临床验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Treatment of relapses in multiple sclerosis (MS) has not advanced beyond steroid use, which reduces acute loss of function, but has little effect on residual disability. Acute loss of function in an MS model (experimental autoimmune encephalomyelitis [EAE]) is partly due to central nervous system (CNS) hypoxia, and function can promptly improve upon breathing oxygen. Here, we investigate the cause of the hypoxia and whether it is due to a deficit in oxygen supply arising from impaired vascular perfusion. We also explore whether the CNS-selective vasodilating agent, nimodipine, may provide a therapy to restore function, and protect from demyelination in 2 MS models. METHODS: A variety of methods have been used to measure basic cardiovascular physiology, spinal oxygenation, mitochondrial function, and tissue perfusion in EAE. RESULTS: We report that the tissue hypoxia in EAE is associated with a profound hypoperfusion of the inflamed spinal cord. Treatment with nimodipine restores spinal oxygenation and can rapidly improve function. Nimodipine therapy also reduces demyelination in both EAE and a model of the early MS lesion. INTERPRETATION: Loss of function in EAE, and demyelination in EAE, and the model of the early MS lesion, seem to be due, at least in part, to tissue hypoxia due to local spinal hypoperfusion. Therapy to improve blood flow not only protects neurological function but also reduces demyelination. We conclude that nimodipine could be repurposed to offer substantial clinical benefit in MS. ANN NEUROL 2020 ANN NEUROL 2020;88:123-136.
引用
- Desai RA, Davies AL, Del Rossi N, et al. Nimodipine Reduces Dysfunction and Demyelination in Models of Multiple Sclerosis. Ann Neurol. 2020. PMID: 32293054. doi:10.1002/ana.25749
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。